V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1

V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1

Item
http://www.wikidata.org/entity/Q36711168
Immunization with plasmid DNA encoding hepatitis C virus envelope E2 antigenic domains induces antibodies whose immune reactivity is linked to the injection modeHIV - 1 SUBTYPES, ITS IMPLICATIONS AND VIRAL DYNAMICS.Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1In vitro neutralization of low dose inocula at physiological concentrations of a monoclonal antibody which protects macaques against SHIV challenge.The role of infant immune responses and genetic factors in preventing HIV-1 acquisition and disease progression.Insertion of primary syncytium-inducing (SI) and non-SI envelope V3 loops in human immunodeficiency virus type 1 (HIV-1) LAI reduces neutralization sensitivity to autologous, but not heterologous, HIV-1 antibodies.Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent iA role for urokinase-type plasminogen activator in human immunodeficiency virus type 1 infection of macrophages.Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization.The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domainIntrahost human immunodeficiency virus type 1 evolution is related to length of the immunocompetent period.Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.An IL-17 peptide-based and virus-like particle vaccine enhances the bioactivity of IL-17 in vitro and in vivo.Vanadium oxoanions and cAMP-dependent protein kinase: an anti-substrate inhibitor.
P2860

V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1

Item
http://www.wikidata.org/entity/Q36711168
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
V3 variability can influence t ...... immunodeficiency virus type 1
@ast
V3 variability can influence t ...... immunodeficiency virus type 1
@en
type
label
V3 variability can influence t ...... immunodeficiency virus type 1
@ast
V3 variability can influence t ...... immunodeficiency virus type 1
@en
prefLabel
V3 variability can influence t ...... immunodeficiency virus type 1
@ast
V3 variability can influence t ...... immunodeficiency virus type 1
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
V3 variability can influence t ...... immunodeficiency virus type 1
@en
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P5875
P698
P932